Atropine Sulfate Injection, USP

Manufacturer
Medical Purchasing Solutions, LLC
Effective date
2023-05-31
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 20:49:48

Label at a glance#

ProductAtropine Sulfate
Active ingredientATROPINE SULFATE
Label structure13 sections

Indications and uses

Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. Atr...

Dosage and administration

The usual dose of atropine sulfate is 0.4 to 0.6 mg. Suggested dosages for pediatric patients are as follows: 7 - 16 lbs. – 0.1 mg                               40 - 65 lbs. – 0.3 mg 17 - 24 lbs. – 0.15 mg                           65 - 90 lbs. – 0.4 mg 24 - 40 lbs. – 0.2 mg                             Over 90 lbs. – 0.4 to 0.6 mg Table of Dosage Equivalents  Atropine Sulfate Solution (mL required)  mg required  1...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

FOR IM, IV OR SC USE

RX only 

DESCRIPTION

DESCRIPTION SECTION

Atropine Sulfate Injection, USP is a sterile solution of atropine sulfate in Water for Injection. Each mL contains Atropine Sulfate 0.4 mg; Sodium Chloride 9 mg; Benzyl Alcohol 9 mg; Water for Injection qs; pH may be adjusted with Sulfuric Acid if necessary. pH 3.0-6.5.
Atropine Sulfate Injection, USP may be given intramuscularly, intravenously or subcutaneously. Atropine is a white crystalline alkaloid which may be extracted from belladonna root or may be produced synthetically. It is used as atropine sulfate because this compound has much greater solubility.
Atropine sulfate is an anticholinergic drug. The empirical formula of atropine sulfate is (C 17H 23NO 3) 2•H 2SO 4•H 2O.
The structural formula is:

structural formula
structural formula

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

The most important therapeutic action of atropine is the inhibition of smooth muscle and glands innervated by postganglionic cholinergic nerves. It also has central nervous system activity, which may be stimulating or depressing depending upon the dose.
Following the administration of usual clinical doses, atropine produces stimulation of the medulla and higher cerebral centers. This effect is manifested by mild central vagal excitation and moderate respiratory stimulation. Atropine sulfate also acts peripherally as a competitive antagonist of the muscarinic actions of acetylcholine. It does not prevent the release of acetylcholine but antagonizes the effect of acetylcholine on the effector cells.
These actions include vasodilation, drying of the mouth, an increase in the pulse rate, inhibition of contractions of the gastrointestinal tract, ureter, and bladder, and reduction of salivary, bronchial, gastric and sweat gland secretions. Following clinical and larger doses, atropine sulfate causes dilation of the pupils and paralysis of accommodation and, in narrow-angle glaucoma, can increase intraocular pressure.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography.
Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Conditions at which inhibition of postganglionic cholinergic nerves are undesirable, such as glaucoma and tachycardia. Also contraindicated in asthma, because the parenteral dose which might relieve asthma would have an excessive drying effect upon mucous plugs in the bronchi. Prostatic hypertrophy, while not a contraindication, requires special attention to signs of urinary retention.

WARNINGS

WARNINGS SECTION

Atropine is a highly potent drug and due care is essential to avoid overdosage, especially with intravenous administration. Pediatric populations are more susceptible than adults to the toxic effects of anticholinergic agents.
Atropine I.V. decreased the rate of mexiletine absorption without altering the relative oral bioavailability; this delay in mexiletine absorption was reversed by the combination of atropine and intravenous metoclopramide during pretreatment for anesthesia. Atropine is not removed by dialysis.
This drug is effective in very low dosage and overdose may cause permanent damage or death, especially in children.
This product contains Benzyl Alcohol which has been associated with a fatal gasping syndrome in infants and neonates.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Doses of 0.5 to 1 mg atropine are mildly stimulating to the CNS. Larger doses may produce mental disturbances; still larger doses are depressing. Death from atropine poisoning, though rare, is usually due to paralysis of the medullary centers.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Atropine causes dryness of the mouth, and when used with other drugs that can cause dryness of the mouth, the effect is additive. Patients receiving chronic treatment can develop blurred vision, and they should not be involved in activities that require good and clear vision.

Drug Interactions

DRUG INTERACTIONS SECTION

Atropine, by slowing gastric emptying and gastrointestinal mobility, may interfere with the absorption of other medications. The effect of atropine on dryness of the mouth may be increased if it is given with other drugs that have anticholinergic action.

Pregnancy Category C

SPL UNCLASSIFIED SECTION

Animal reproduction studies have not been conducted with atropine sulfate. It is also not known whether atropine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Atropine sulfate should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Caution should be exercised when atropine sulfate is administered to a nursing mother.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Individual tolerance varies greatly, but these systemic doses are likely to produce the following effects:

0.5 mg - Slight dryness of nose and mouth, bradycardia.
1 mg - Greater dryness of nose and mouth, with thirst; slowing, then acceleration of heart; slight mydriasis.
2 mg - Very dry mouth, tachycardia, with palpitation, mydriasis, slight blurring of near vision.
5 mg - Increase in the above symptoms plus disturbance of speech, difficulty in swallowing, headache, hot, dry skin, restlessness with asthenia.
10 mg and over - Above symptoms to extreme degree, plus ataxia, excitement, disorentation, hallucinations, delirium and coma.
65 mg - May be fatal.

A scarlatiniform rash may occur. Atropine may produce fever, particularly in children, through inhibition of heat loss by evaporation. Although large doses of atropine may cause an alarming condition, recovery is usual.

OVERDOSAGE

OVERDOSAGE SECTION

Toxic doses from atropine are not uncommon, especially in children.

Symptoms

SPL UNCLASSIFIED SECTION

The principle manifestations of poisoning with atropine are delirium, tachycardia and fever.

Treatment

SPL UNCLASSIFIED SECTION

In the treatment of atropine poisoning, respiratory assistance and symptomatic support are indicated. Physostigmine salicylate, 1 to 5 mL of a dilution containing 1 mg per 5 mL of saline, should be administered intravenously. Administer the smaller dose in children and administer in not less than 2 minutes. Monitor with ECG. Medication can be repeated every 5 minutes for a total dose of 2 mg in children and every 30 minutes for a total dose of 6 mg in adults.
The fatal dose of atropine in children may be as low as 10 mg. In an adult, recovery after 1,000 mg of atropine sulfate has been reported. Death is usually due to paralysis of the medullary centers. The fatality rate is less than 1%. If the patient survives 24 hours, they will probably recover.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The usual dose of atropine sulfate is 0.4 to 0.6 mg. Suggested dosages for pediatric patients are as follows:
7 - 16 lbs. – 0.1 mg                               40 - 65 lbs. – 0.3 mg
17 - 24 lbs. – 0.15 mg                           65 - 90 lbs. – 0.4 mg
24 - 40 lbs. – 0.2 mg                             Over 90 lbs. – 0.4 to 0.6 mg

Table of Dosage Equivalents
 Atropine Sulfate Solution (mL required)
 mg required 1 mg per mL 0.4 mg per mL
 1 1 
 0.80 0.80 
 0.60 0.60 
 0.50 0.50 
 0.40 0.40 1
 0.30 0.30 0.75
 0.25 0.25 0.63
 0.20 0.20 0.50
 0.18 0.18 0.45
 0.15 0.15 0.38
 0.12 0.12 0.30
 0.10 0.10 0.25

These doses may be exceeded in certain cases.
For hypotonic radiography of the gastrointestinal tract, the usual adult dose is 1 mg intramuscularly.
Adults suspected of contact with organic phosporous insecticides of the parathion type should be given atropine sulfate 0.8 mg intramuscularly. If an atropine effect is not apparent within 30 minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements and excessive sweating, salivation and bronchial secretion), atropine sulfate 2 mg should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to 2 or 3 times of this dose (4 to 6 mg) may be required in severe cases.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

HOW SUPPLIED SECTION

Atropine Sulfate Injection, USP is available in the following:
0.4 mg/mL
20 mL multiple dose vial packaged in 10s (NDC 0641-6006-10)
Use only if solution is clear and seal intact.
Store at 20°-25°C (68°-77°F), excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature].

To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For Product Inquiry call 1-877-845-0689.

Manufactured by:

West-Ward Logo
West-Ward Logo

WEST-WARD
PHARMACEUTICALS

Eatontown, NJ 07724 USA

Revised June 2011                                                                       

462-416-01

Vial Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Atropine Sulfate Injection, USP

8 mg/20 mL (0.4 mg/mL)

1- 20 mL Multiple Dose Vial

atrovialatrovial

PACKAGE: OUTER LABEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 71872-7037-1

Atropine Sulfate Injection, USP

8 mg/20 mL

1 - 20 mL Vial

FOR IM, IV OR SC USE.

Rx Only

atrolabelatrolabel

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1190776atropine sulfate 0.4 MG/ML Injectable SolutionPSN4
1190776atropine sulfate 0.4 MG/ML Injectable SolutionSCD4
1190776atropine sulfate 1 MG per 2.5 ML Injectable SolutionSY4
1190776atropine sulfate 1.2 MG per 3 ML Injectable SolutionSY4
1190776atropine sulfate 2 MG per 5 ML Injectable SolutionSY4
1190776atropine sulfate 8 MG per 20 ML Injectable SolutionSY4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ATROPINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
6c78bd43-efb4-4aeb-b7d8-eff1532f7822Product name420250801
41231c1e-8789-4da7-ac52-77fa90a85bf5Product name220250304
e77ab9a2-80cf-4832-bff0-469bbc7cbcd0Product name220250214
5f84b7a7-523a-f042-dffb-1dadcd9b2407Product name420240110
0cbc6fb2-78c0-4b88-98f0-a4cc76ff95caProduct name120230719
04cd5dc0-102f-46cb-8dbc-ca38dd2628d0Product name320230317
dfd25202-b8d2-4628-9213-f3e0f9eafce5Product name420210513
4199bf9b-4718-828a-6dd6-ac2fbbd61687Product name120140508
4edd8af5-cea7-ae42-8023-e91c5335db1dProduct name120140508
d3908afb-7784-440f-c406-88294732d36aProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
71872-7037-1Atropine Sulfate1 in 1 BAGINJECTION14
71872-7037-1Atropine Sulfate20 mL in 1 VIALINJECTION204

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
71872-7037ATROPINE SULFATE INJECTION [MEDICAL PURCHASING SOLUTIONS, LLC]4Current NDC, Legacy NDC, 2 package rows20230602_6bb51b79-ae86-aebf-e053-2991aa0a8d33.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0641-6006-01ML - Milliliter0641-60060dd1cebf-afb5-463c-8066-2ae1248537db12012-07-24
0641-6006-10ML - Milliliter0641-600650fad021-aa7f-43ab-b295-6c10da590ef312012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
71872-703771872-7037-1
0641-6006

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 5 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Atropine SulfateATROPINE SULFATEMedical Purchasing Solutions, LLC6bb51b79-ae86-aebf-e053-2991aa0a8d332023-05-31Warnings, Adverse reactionsExact identifier
ndc (package): 71872-7037-1
ndc (product): 71872-7037
ndc11 (package): 71872703701
spl id: fd021c33-19cc-b7f5-e053-6394a90a9302
spl set id: 6bb51b79-ae86-aebf-e053-2991aa0a8d33

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.